Digital Therapeutic Testing Platform ixlayer Expands Collaborations
The platforms are designed to improve patient engagement and adherence.
ixlayer, a health testing platform, announced the continued expansion of its collaborations with biopharma innovators. Adding to a growing list of relationships in the biopharma space, ixlayer supports advances in digital therapeutics and decentralized clinical trials (DCTs), with remote diagnostic testing capabilities that enable patient support and clinical research technologies to realize the full potential of their impact on patient care.
ixlayer’s lab testing program offers multiple testing formats, including flexible digital options, and thousands of testing combinations. The company offers multi-modality sample selection options, such as at-home self-collect, at-home assisted collection(i.e., mobile phlebotomy), and sample collection at a local patient service center.
“ixlayer helps drive patient engagement through lab testing – because when patients can monitor their health, they more clearly see the impact of the treatment and stay on their drug/therapy,” said Shawn Tedman, Vice President of Innovation at ixlayer. “By utilizing ixlayer’s remote health testing to enhance digital therapeutics offerings, these collaborations can amplify the impact of exciting new health technologies and provide the missing link to enhance patient engagement.”
This story continues here.
